⌕
Aktis Oncology · AKTS · Nasdaq
Tenet 52 · Mixed
Compare
$16.16−2.77%At closeTenet 52 · Mixed
$16.16−0.46 (−2.77%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Aktis Oncology (AKTS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 12, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress

Initiated the Company's third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors Started first backfill cohorts in the ongoing Phase 1b NECTINIUM-…

● Zacks Investment ResearchNov 11, 2026 · 17:21 ET
Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?

The mean of analysts' price targets for Aktis (AKTS) points to a 105.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings …

● Seeking AlphaOct 14, 2026 · 16:27 ET
Aktis Oncology: Padcev Is Building The Market It Wants

Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. AKTS has a cash runway into 2029, supported by $517.3M in cash and a $1.2B+ partnership with Eli …

● GlobeNewsWireOct 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3

Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors Enrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-251…

● Seeking AlphaSep 16, 2026 · 12:01 ET
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just AKTS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.